Medtronic (MDT) Faces Fresh Scrutiny On $88 Million Verdict As Fair Value Stays In Focus
Medtronic (MDT) is under renewed scrutiny after a federal jury ordered the company to pay US$88 million in compensatory damages tied to hernia mesh products from its Covidien unit, with Medtronic planning to challenge the verdict.
See our latest analysis for Medtronic.
Despite the legal setback, Medtronic’s recent share price performance has improved, with a 4.72% 7 day share price return and 18.04% 90 day share price return. The 1 year total shareholder return of 1.31% points to more muted longer term gains.
If you are reassessing healthcare exposure after this verdict, it can be useful to look across the sector and see which companies are drawing interest through AI enabled treatments and tools via the 42 healthcare AI stocks
After Medtronic’s sharp recent move and a share price near US$91, the gap between today’s price, analyst targets and intrinsic value estimates is tight. So where does fair value really sit as you weigh the legal and growth story?
Most Popular Narrative: Fairly Valued
The most followed Medtronic narrative pegs fair value at $90.37, which sits very close to the last close of $91.27, so the story hinges on the underlying assumptions rather than a big pricing gap.
Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.
Want to see what sits behind this tight fair value range for Medtronic? The narrative leans on steady revenue expansion, disciplined margins, and a future earnings multiple that assumes patient compounding. Curious which specific growth and profitability assumptions justify pricing Medtronic so close to calculated fair value?
Result: Fair Value of $90.37 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Medtronic’s hernia mesh litigation and any shift in assumptions for its future P/E or profit margins could quickly challenge this tight fair value story.
Find out about the key risks to this Medtronic narrative.
Another View: Medtronic Through The Earnings Multiple
While the user narrative pegs Medtronic close to fair value at $90.37, the earnings multiple tells a slightly different story. Medtronic trades on a P/E of 24.3x versus a fair ratio of 30.7x, the Medical Equipment industry at 26.2x and peers at 33.8x. That gap suggests the market is pricing in some caution. The question is whether you see that as risk, or room for the P/E to move toward the fair ratio over time.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed sentiment around Medtronic right now, it helps to look past headlines and weigh the details for yourself. To see what optimism in the data looks like in practice, review the company’s 5 key rewards
Looking for more Medtronic sized investment ideas?
Do not stop your research with Medtronic. Use the Simply Wall St screener to line up fresh ideas so you are not caught relying on a single stock story.
- Scan for strong cash generation and balance sheet strength by reviewing the solid balance sheet and fundamentals stocks screener (51 results).
- Hunt for quality at a measured price by checking the 52 high quality undervalued stocks.
- Target regular income opportunities by analysing the 10 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com